a16z Bio + Health’s Post

A16z Bio podcasts on Glp-1s

Grateful to have joined an energizing panel conversation at today’s MedCity #INVEST2024 conference alongside Betty Pio, Alexander Singh, Sheila Shah. The panel posed an important question: How are Glp-1 Drugs Reshaping the Healthcare Industry? Here were my biggest takeaways: 🎲 The stakes are higher than they’ve ever been, and those who are interested in driving long-term results for patients are focused on clinically comprehensive, evidence-based care, not transactional, medication-only care. 💪 The implications of GLP-1s are wide-ranging, as we’ve seen so many other industries adapt to meet the consumer demand. As a society, do we believe that gyms delivering GLP-1s could be a mechanism to help improve access, or would it more likely lead to less effective care? 📣 Weight care is one element of metabolic care — clinicians understand this, and consumers are beginning to understand this, too. What implications will we see as patients become even more sophisticated in their understanding of obesity as a disease? And how can our industry help to bridge the education gap and offer wraparound care? 💊 I continue to hear healthy skepticism regarding any weight care companies that exclusively rely on one medication (e.g. only compounded GLP-1s, branded GLP-1s, or generics). Further, despite consumer weariness (largely due to years of being told that weight should be a quick-fix), the evidence continues to show that long-term use of medication is needed to keep the weight off. Care providers who are equipped to meet a variety of medical and financial needs (the same way we’d practice in academic centers of excellence) will be best suited to deliver care that stands the test of time. ⚖ Related to the point above, we must continue to consider ways to design care that can reach the populations who need it most. If we are creating care plans that are financially unsustainable, who are we helping? How can we leverage the incredible advancement in obesity care that GLP-1s present in a way that doesn’t make health care disparities worse? I’d love to hear your thoughts! 👇 :

Proud to support the publication of the report “Therapeutic Adherence: A Challenge to European Patient-Centric Health Systems” developed and written by a coalition of Patient Associations, Scientific Societies and Industry. Calling on EU policymakers to seize this opportunity, using the report's solutions to benefit #patients, Servier is commited and will continue to follow-up until there is a concrete progress on that topic, which has human and economic consequences. Indeed, today in #Europe we estimate that about 200,000 people die because they don’t rigorously take their prescription, 9% of cardiovascular events could be attributed to poor adherence, it’s time to act! Let's join forces, adopt a holistic approach to therapeutic adherence, and turn policy into action. #TherapeuticAdherence Congratulations and special thanks to the Chairmen Pr Atul Pathak and Claudio Borghi and to MEP Istvan Ujhelyi. 👉 https://lnkd.in/gSzBPkHX 🙏 Associations: Aistė Štaraitė Global Heart Hub & Steven Macari Scientific Societies: World Heart Federation, International Society of Hypertension, European Society of Cardiology, ESH European Society of Hypertension, European Diabetes Forum (EUDF), Sociedade Portuguesa de Hipertensão  Industry: OMRON Group 🙏 Agnes DEVOIS, MD, Sybille Billiard, Olivier Nosjean, Anne-Claire Julienne

Access the March issue of Kidney360! Discover the latest educational papers on cutting edge clinical research, review engaging editorials, explore global perspective pieces, and more. Read this month’s top picks: ➡ What Are the Impacts of Introducing an SGLT2 Inhibitor after a Recent Episode of Acute Kidney Injury?: https://bit.ly/3TUNns5 ➡ Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD): https://bit.ly/43Fewm4 ➡ Peritoneal Dialysis (PD) Patient and Nurse Preferences around Novel and Standard Automated PD Device Features: https://bit.ly/3IUPPJ5 ➡ Patient-Level and Center-Level Factors Associated with Required Predonation Weight Loss among Obese Living Kidney Donors: https://bit.ly/4ajk34E ➡ Global Perspectives in AKI: Sri Lanka: https://bit.ly/3TT6Aus Learn from these articles and more: https://bit.ly/3Ued87h   Pro Tip: Take advantage of the Read Out Loud feature to listen to the latest research while on the go. Click the “listen” speaker in your article of choice to enjoy listening anywhere, anytime.

A recent study on DTx released by Peterson Health Technology Institute (PHTI) on type 2 diabetes misses the mark. Here at Health Parliament, we believe its limitations paint an incomplete picture: - Limited Scope: Just 8 DTx tools and only type 2 diabetes? This ignores the vast potential of DTx solutions! - Incomplete Evaluation: Focusing only on HbA1c misses DTx's impact on lifestyle changes, a key factor in disease management. - Misleading Generalizations: Extrapolating results to the entire DTx industry is inaccurate. - DTx offers immense promise, especially in regions with limited healthcare access! Here's what we need to do to unlock its true potential: - Long-Term Studies: We need robust research comparing DTx to traditional methods over time. - Focus on Underserved Regions: Let's prioritize DTx solutions tailored to resource-constrained areas. - Collaboration is Key: Researchers, healthcare providers, and DTx developers must work together for continuous improvement. Read the complete statement below. Health Parliament’s Asia Pacific DTx Leadership Alliance is committed to responsible innovation. We advocate for rigorous, long-term studies that explore the full potential of DTx in Chronic Disease Management. Ready to learn more? Download the full report on ‘Promise and Potential of Digital Therapeutics for DCDM’ at https://lnkd.in/d4ShfHqr #health #healthcare #digitalhealth #publichealth #publicpolicy #DTx #leadership #alliance #chronicdisease #diabetes #study #therapeutics #innovation

Happening today @ 1pm EST! Please join Real Chemistry's own Rita Glaze-Rowe as she sits down with STAT editor Jesse McQuarters & leading obesity medicine expert, Courtney Younglove, M.D., FOMA, FACOG, DABOM, for a thought-provoking webinar conversation about the rapidly transforming obesity market, driven by GLP-1s. They'll share their insights & experiences, spotlighting the most important questions healthcare leaders should be asking themselves right now to prepare for the realities & ripple effects.

In the ever-evolving landscape of healthcare, understanding patient access to specialized care is paramount. As part of our commitment to fostering meaningful discussions and solutions in this realm, we're proud to share that our COO, Rohit Rustagi, will be presenting his insights at the 2023 World Obesity Conference in Boston, MA this coming week! Rohit's talk will delve into the intricacies of regional disparities in obesity care access, focusing on wait times across top U.S. hospitals. This topic is not just about numbers, but about real people waiting for essential medical attention. Our goal is to: 1) Help audiences grasp the current barriers patients face when seeking obesity treatment, 2) Explore innovative strategies to enhance patient access and reduce wait times, and 3) Contemplate on the urgent necessity for a broader understanding and approach to obesity medicine and the role of health systems in addressing it.  🔗 Link to the abstract in comments!

I talk a lot about the neccesity and potential of partnering with patients to create innovative solutions in healthcare. This very interesting work from the Karolinska institue tries to look at the research and what is out there. Key Points: 💡 Patient driven innovation is a real driver of solutions to key unmet needs faced by chronic patients and caregivers. With 83 peer reviewed research included in the review. 💡 Three categories of unmet needs were addressed by these innovations: access to self-care support tools, open sharing of information and knowledge, and patient agency in self-care and healthcare decisions. 💡Of the 83 articles - 22% recorded outcomes of the innovative solutions. Most did not record any adverse or negative events, which may elude to some bias. 💡Many of the solutions were around type 1 diabetes and childrens diesease which is interesting on its own. 💡The research is part of a very interesting research group: Patients in the driver’s seat! A multimethod partnership program on patient-driven innovations. A very interesting group advnacing participatory medicine and research. Link to the article ->https://lnkd.in/db7PURpk Link to the Karolnska research group -> https://lnkd.in/de6udPcv #patientcare #patientinnovation #innovationinhealthcare #participatoryresearch

I have spent some great days at ERA conference 2024 in Stockholm, by e.g. talking to colleagues, nephrologists, societies and listened into great talks to get the newest updates on chronic kidney disease. ->Maybe you did not know about chronic kidney disease. CKD.. - is worldwide extremely common: 844 million patients in 2017 - 1 in 10 people in the general population have CKD and - by 2040 will be ranked as 5th important disease for death - 9 out of 10 persons with CKD did not know they had the disease - 7-10 million patients need treatment every year -> 2.5m receive it everyone else dies - is the only Non-Communicational Disease with rising year-on-year mortality - CKD awareness in public: the news does not reflect what humans die from – in the media especially they focus on terrorism, homicide and suicide and less info about drug overdose, heart disease or kidney disease - the disease gets diagnosed by far too late   -> Highlight (-> for patients) FLOW key results (e.g.24% risk reduction for occurrence of major kidney event and 20% lower risk of overall death -> and the need for further research on effect of combining the now available therapies (SGLT2, GLP1 RA, NS-MRAs, RAS Blockers)   -> Take away -Barriers to appropriate medication prescribing and use in CKD -> Trust in healthcare system, burnout of clinicians, socio economic (Low-Middel Income countries), not aligned or missing guidelines, lack of CKD policies and drug prices -What it takes to address the pandemic, e.g.: 1.      Improved access to care 2.      Better prevention 3.      Greater awareness and education 4.      Increased funding for R&D 5.      Increased screening and diagnosing 6.      Multidisciplinary care teams needed to optimize care for patients 7.      Educating patients on their diagnosis is key for stimulating engagement in their kidney health - Due to the importance, CKD should become a priority topic for World Health Organization to create awareness and the good thing is.. .. Digital Health solutions can support to solve the pandemic by, e.g early diagnosis and screening of patients through EHR data, AI algorythms and analysis of lab reports, telemedicine (Doctor to Doctor education), home tesing etc  #ERA24 #CKD #chronickidneydisease #digitalhealth

3 reasons why this paper makes me angry and sad: 1. Why shouldn’t this study be done more frequently than once every 10 years? 2. Why only 4,000 people were studied to set the standard for 332 million people? 3. Why can’t we use real world data from 300 million EHR records out there to come up with better predictions? Doctors and people not having this type of current information costs millions of lives and billions of dollars in healthcare spending! Do you know why? Comments? #innovatormd #founderinstitute #siricatherapeutics #prevention #healthcarecosts #healthoutcomes